CA2666112A1 - Pyrrolydine derivatives as iap inhibitors - Google Patents

Pyrrolydine derivatives as iap inhibitors Download PDF

Info

Publication number
CA2666112A1
CA2666112A1 CA002666112A CA2666112A CA2666112A1 CA 2666112 A1 CA2666112 A1 CA 2666112A1 CA 002666112 A CA002666112 A CA 002666112A CA 2666112 A CA2666112 A CA 2666112A CA 2666112 A1 CA2666112 A1 CA 2666112A1
Authority
CA
Canada
Prior art keywords
methylamino
pyrrolidin
cyclohexyl
ethyl
propionamide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002666112A
Other languages
English (en)
French (fr)
Inventor
Mark G. Charest
Christine Hiu-Tung Chen
Ming Chen
Zhuoliang Chen
Miao Dai
Feng He
Huangshu Lei
Christopher Straub
Run-Ming David Wang
Leigh Zawel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2666112A1 publication Critical patent/CA2666112A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06191Dipeptides containing heteroatoms different from O, S, or N
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05Dipeptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
CA002666112A 2006-10-12 2007-10-10 Pyrrolydine derivatives as iap inhibitors Abandoned CA2666112A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US82923406P 2006-10-12 2006-10-12
US60/829,234 2006-10-12
PCT/US2007/080875 WO2008045905A1 (en) 2006-10-12 2007-10-10 Pyrrolydine derivatives as iap inhibitors

Publications (1)

Publication Number Publication Date
CA2666112A1 true CA2666112A1 (en) 2008-04-17

Family

ID=38984426

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002666112A Abandoned CA2666112A1 (en) 2006-10-12 2007-10-10 Pyrrolydine derivatives as iap inhibitors

Country Status (11)

Country Link
US (1) US8044209B2 (https=)
EP (1) EP2102229B1 (https=)
JP (1) JP5190062B2 (https=)
KR (1) KR20090065548A (https=)
CN (1) CN101595121A (https=)
AU (1) AU2007307763A1 (https=)
BR (1) BRPI0719221A2 (https=)
CA (1) CA2666112A1 (https=)
MX (1) MX2009003834A (https=)
RU (1) RU2009117701A (https=)
WO (1) WO2008045905A1 (https=)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2007007195A (es) 2004-12-20 2007-10-08 Genentech Inc Inhibidores de pirrolidina de iap.
US7772177B2 (en) 2005-05-18 2010-08-10 Aegera Therapeutics, Inc. BIR domain binding compounds
WO2007048224A1 (en) 2005-10-25 2007-05-03 Aegera Therapeutics Inc. Iap bir domain binding compounds
WO2007106192A2 (en) 2005-12-19 2007-09-20 Genentech, Inc. Inhibitors of iap
TWI504597B (zh) 2006-03-16 2015-10-21 Pharmascience Inc 結合於細胞凋亡抑制蛋白(iap)之桿狀病毒iap重複序列(bir)區域之化合物
US8110681B2 (en) 2006-03-17 2012-02-07 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Compounds for the treatment of spinal muscular atrophy and other uses
AU2007250443B2 (en) 2006-05-16 2013-06-13 Pharmascience Inc. IAP BIR domain binding compounds
PE20110220A1 (es) * 2006-08-02 2011-04-11 Novartis Ag DERIVADOS DE 2-OXO-ETIL-AMINO-PROPIONAMIDA-PIRROLIDIN-2-IL-SUSTITUIDOS COMO INHIBIDORES DEL ENLACE DE LA PROTEINA Smac AL INHIBIDOR DE LA PROTEINA DE APOPTOSIS
US8063218B2 (en) * 2006-12-19 2011-11-22 Genentech, Inc. Imidazopyridine inhibitors of IAP
PE20130150A1 (es) 2007-04-30 2013-02-27 Genentech Inc Inhibidores de las iap
US9750729B2 (en) 2008-05-16 2017-09-05 Dana-Farber Cancer Institute, Inc. Immunomodulation by IAP inhibitors
CN102171209A (zh) 2008-08-02 2011-08-31 健泰科生物技术公司 Iap抑制剂
JP5693452B2 (ja) * 2008-08-04 2015-04-01 シーエイチディーアイ ファウンデーション,インコーポレーテッド 特定のキヌレニン−3−モノオキシゲナーゼインヒビター、医薬組成物およびそれらの使用方法
JP2012500272A (ja) * 2008-08-16 2012-01-05 ジェネンテック, インコーポレイテッド Iapのアザインドールインヒビター
US9643922B2 (en) 2008-08-18 2017-05-09 Yale University MIF modulators
PE20110368A1 (es) * 2008-08-18 2011-06-13 Univ Yale Moduladores de mif
US9540322B2 (en) 2008-08-18 2017-01-10 Yale University MIF modulators
US20100317593A1 (en) * 2009-06-12 2010-12-16 Astrazeneca Ab 2,3-dihydro-1h-indene compounds
UY32826A (es) 2009-08-04 2011-02-28 Takeda Pharmaceutical Compuestos heterocíclicos
KR20120118008A (ko) 2009-12-18 2012-10-25 아이데닉스 파마슈티칼스, 인코포레이티드 5,5-융합 아릴렌 또는 헤테로아릴렌 간염 c 바이러스 억제제
WO2011098904A1 (en) 2010-02-12 2011-08-18 Aegera Therapeutics, Inc. Iap bir domain binding compounds
US8835458B2 (en) * 2010-08-31 2014-09-16 Hanmi Science Co., Ltd Quinoline or quinazoline derivatives with apoptosis inducing activity on cells
UY33794A (es) * 2010-12-13 2012-07-31 Novartis Ag Inhibidores diméricos de las iap
US20130266590A1 (en) 2010-12-13 2013-10-10 Novartis Ag Dimeric iap inhibitors
JP2014094886A (ja) * 2011-02-28 2014-05-22 Nippon Chemiphar Co Ltd Gpr119作動薬
GB201106817D0 (en) 2011-04-21 2011-06-01 Astex Therapeutics Ltd New compound
CA2841981A1 (en) * 2011-07-28 2013-01-31 Chdi Foundation, Inc. Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
MX2014002459A (es) 2011-08-30 2014-04-10 Chdi Foundation Inc Inhibidores de quinurenina-3-monooxigenasa, composiciones farmaceuticas y metodos de uso de los mismos.
SI2750677T1 (sl) 2011-08-30 2017-10-30 Chdi Foundation, Inc. Inhibitorji kinurenin-3-monooksigenaze, farmacevtski sestavki in postopki njihove uporabe
NO2755614T3 (https=) 2012-01-03 2018-03-31
US9980973B2 (en) 2012-10-19 2018-05-29 Astex Therapeutics Limited Bicyclic heterocycle compounds and their uses in therapy
GB201218864D0 (en) * 2012-10-19 2012-12-05 Astex Therapeutics Ltd Bicyclic heterocycle compounds and their uses in therapy
JP6321020B2 (ja) * 2012-10-19 2018-05-09 アステックス、セラピューティックス、リミテッドAstex Therapeutics Limited 二環式複素環化合物およびそれらの治療での使用
JP6324976B2 (ja) * 2012-10-19 2018-05-16 アステックス、セラピューティックス、リミテッドAstex Therapeutics Limited 二環式複素環化合物およびそれらの治療での使用
GB201218850D0 (en) * 2012-10-19 2012-12-05 Astex Therapeutics Ltd Bicyclic heterocycle compounds and their uses in therapy
GB201218862D0 (en) 2012-10-19 2012-12-05 Astex Therapeutics Ltd Bicyclic heterocycle compounds and their uses in therapy
ES2883289T3 (es) 2013-12-20 2021-12-07 Astex Therapeutics Ltd Compuestos heterocíclicos bicíclicos y sus usos en terapia
WO2015109391A1 (en) 2014-01-24 2015-07-30 Children's Hospital Of Eastern Ontario Research Institute Inc. Smc combination therapy for the treatment of cancer
CN106715421A (zh) 2014-07-17 2017-05-24 Chdi基金会股份有限公司 用于治疗hiv相关病症的方法和组合物
KR20170004160A (ko) * 2015-07-01 2017-01-11 엘지전자 주식회사 이동단말기 및 그 제어방법
US12084472B2 (en) 2015-12-18 2024-09-10 Ardelyx, Inc. Substituted 4-phenyl pyridine compounds as non-systemic TGR5 agonists
TWI773657B (zh) 2015-12-18 2022-08-11 美商亞德利克斯公司 作爲非全身tgr5促效劑之經取代之4-苯基吡啶化合物
KR102707188B1 (ko) * 2017-11-13 2024-09-13 치아타이 티안큉 파마수티컬 그룹 주식회사 Iap 억제제로서 유용한 smac 모방물 및 그 용도
WO2020027225A1 (ja) 2018-07-31 2020-02-06 ファイメクス株式会社 複素環化合物
EP3936126A4 (en) * 2019-03-07 2022-12-21 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. COMBINATION OF IAP INHIBITOR AND IMMUNOCHECK POINT INHIBITOR
MX2021013729A (es) * 2019-05-10 2021-12-10 Chia Tai Tianqing Pharmaceutical Group Co Ltd Cristalina de imitador smac utilizado como inhibidor de iap y metodo de preparacion del mismo.
WO2021020585A1 (ja) 2019-07-31 2021-02-04 ファイメクス株式会社 複素環化合物
CN112521372B (zh) * 2019-09-18 2022-07-08 南京华威医药科技集团有限公司 一种细胞凋亡蛋白抑制剂及其制备方法和用途
JP2023510426A (ja) 2020-01-20 2023-03-13 アストラゼネカ・アクチエボラーグ 癌を治療するための上皮細胞増殖因子受容体チロシンキナーゼ阻害剤

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR200200767T1 (tr) 2000-05-23 2002-09-23 Vertex Pharmaceuticals Incorporated Kaspaz engelleyiciler ve kullanımları
WO2004005248A1 (en) 2002-07-02 2004-01-15 Novartis Ag Peptide inhibitors of smac protein binding to inhibitor of apoptosis proteins (iap)
ATE415413T1 (de) * 2002-07-15 2008-12-15 Univ Princeton Iap-bindende verbindungen
RS52545B (sr) 2004-04-07 2013-04-30 Novartis Ag Inhibitori protein apoptoze (iap)
BRPI0511350A (pt) 2004-07-02 2007-12-04 Genentech Inc composto, métodos de indução da apoptose em uma célula, de sensibilização de uma célula à um sinal apoptótico, de inibição da ligação de uma proteìna iap e de tratamento de uma doença e cáncer e usos de um composto
MX2007007195A (es) * 2004-12-20 2007-10-08 Genentech Inc Inhibidores de pirrolidina de iap.
WO2007106192A2 (en) * 2005-12-19 2007-09-20 Genentech, Inc. Inhibitors of iap

Also Published As

Publication number Publication date
KR20090065548A (ko) 2009-06-22
CN101595121A (zh) 2009-12-02
WO2008045905A1 (en) 2008-04-17
US8044209B2 (en) 2011-10-25
BRPI0719221A2 (pt) 2014-03-18
US20110015232A1 (en) 2011-01-20
EP2102229A1 (en) 2009-09-23
RU2009117701A (ru) 2010-11-20
JP2010506847A (ja) 2010-03-04
MX2009003834A (es) 2009-04-22
AU2007307763A1 (en) 2008-04-17
JP5190062B2 (ja) 2013-04-24
EP2102229B1 (en) 2014-03-26

Similar Documents

Publication Publication Date Title
EP2102229B1 (en) Pyrrolydine derivatives as iap inhibitors
CA2658525C (en) Smac peptidomimetics useful as iap inhibitors
KR20130140219A (ko) C형 간염 바이러스 복제의 억제제
AU2006255084A1 (en) Organic compounds
AU2007332861A1 (en) 6-oxo.-1, 6-dihydropyrimidin-2-yls in the treatment of proliferative diseases
HK1176613B (en) Intermediate compounds for preparing smac peptidomimetics
HK1127616B (en) Smac peptidomimetics useful as iap inhibitors
HK1176612A (en) Organic compounds
AU2014200550A1 (en) Inhibitors of hepatitis C virus replication

Legal Events

Date Code Title Description
FZDE Discontinued